预约演示
更新于：2026-08-18
Aripiprazole
阿立哌唑
更新于：2026-08-18
概要
基本信息
简介阿立哌唑，商品名 Abilify Discmelt®，是一种非典型抗精神病药物，用于治疗多种情绪和精神病，包括但不限于精神分裂症、I 型双相情感障碍、重度抑郁症、易激惹相关疾病、自闭症和图雷特综合症。作用机制为5-HT2A 激动剂和 D2 受体激动剂。阿立哌唑于2002 年首次获得美国 FDA 批准，由大冢控股开发。它的主要适应症是用于治疗精神分裂症。 |
药物类型 小分子化药 |
别名 ABILIFY MAINTENA、Abilify MyCite、Abilify Prolonged Release Aqueous Suspension + [36] |
作用方式 激动剂、拮抗剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H27Cl2N3O2 |
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N |
CAS号129722-12-9 |
关联
540
项与 阿立哌唑 相关的临床试验NCT07714213
Prospective, Randomized, Double-blind, Placebo-controlled Phase 2a Trial of Low-dose Aripiprazole in Patients With Neuropsychiatric Impairment in Post-acute Infectious Syndrome (PAIS) Including Post-COVID-19 Condition (PCC)
NCT05545891
A Double-Blind, Placebo Controlled Study of Aripiprazole in Body Focused Repetitive Behaviors
JPRN-jRCT2031260174
A multicenter, open-label, clinical pharmacology study to evaluate the pharmacokinetics and safety of repeated administration of aripiprazole IM depot 2-month formulation (OPC-14597 2M IMD) in patients with schizophrenia
100 项与 阿立哌唑 相关的临床结果
登录后查看更多信息
100 项与 阿立哌唑 相关的转化医学
登录后查看更多信息
100 项与 阿立哌唑 相关的专利（医药）
登录后查看更多信息
6,411
项与 阿立哌唑 相关的文献（医药）2027-01-01CLINICA CHIMICA ACTA
Development and validation of patient-based exponentially weighted moving average quality control models for three antipsychotic drugs and their metabolites by LC-MS/MS
Article
作者: Pu, Yungang ; Ruan, Canjun ; Guo, Guixin ; Ling, Sihai ; Guo, Qi ; Zhou, Chunyan ; Liu, Xiangyi ; Liu, Chengeng ; He, Jing
BACKGROUND:
Therapeutic drug monitoring of antipsychotics is essential for personalized dosing. Traditional internal quality control (IQC) lacks real-time capability, potentially delaying error detection. Patient-Based Real-Time Quality Control (PBRTQC) can overcome this by continuously analyzing patient data. However, its application to antipsychotic drug assays remains underexplored.
OBJECTIVE:
To develop and validate novel PBRTQC models based on the exponentially weighted moving average (EWMA) for the real-time monitoring of three first-line antipsychotics (aripiprazole, clozapine, quetiapine) and their major metabolites-addressing a critical gap in laboratory quality assurance for psychiatric pharmacotherapy.
METHODS:
Chronologically ordered concentration data were split into training and validation sets. Truncation limits were optimized via trimming and winsorization. Multiple EWMA models with different weighting factors (λ) were evaluated. Model selection was based on the false positive alarm rate (FAR) and the average number of patients before error detection (ANPed), validated using simulated constant and proportional errors.
RESULTS:
Optimal models for most analytes employed trimming at 1.5 standard deviation (SD) with λ = 0.03. The introduced PBRTQC system demonstrated high sensitivity: for a 15% analytical bias, the ANPed was <20 for quetiapine, <40 for desalkylquetiapine and aripiprazole, <50 for dehydroaripiprazole, and < 30 for clozapine/norclozapine. All ANPeds fell below 20 at a 30% bias, confirming effective error detection.
CONCLUSION:
EWMA-based PBRTQC models specifically tailored for antipsychotic drug monitoring were successfully established. The models provide a practical, real-time complement to traditional IQC, enabling the early detection of analytical shifts and enhancing the reliability of laboratory data for clinical decision-making in psychiatry.
2026-11-01JOURNAL OF AFFECTIVE DISORDERS
Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
Article
作者: Zhang, Zhen ; Bell Lynum, Karimah S ; Atkins, Norman ; Citrome, Leslie ; Hutson Walker, Anne M
BACKGROUND:
This post hoc analysis assessed the benefit-risk profile of aripiprazole once-monthly 400 mg (AOM 400) as a long-term maintenance treatment in patients diagnosed with bipolar I disorder (BP-I), using the evidence-based metrics of number needed to treat (NNT), number needed to harm (NNH), and the likelihood to be helped or harmed (LHH).
METHODS:
Data were derived from a double-blind, randomized withdrawal study that evaluated the efficacy and safety/tolerability of AOM 400 versus placebo over 52 weeks (NCT01567527). The main efficacy outcome was the proportion of patients free from recurrence of any mood episode, while the main safety/tolerability outcome was the incidence of patient discontinuation due to treatment-emergent adverse events (TEAEs).
RESULTS:
Overall, 73.5% of 132 patients randomized to AOM 400 and 48.9% of 133 patients randomized to placebo were free from recurrence of any mood episode at Week 52 (NNT = 5 [95% CI: 3,8]). NNT (95% CI) values were 5 (4, 9), 4 (3, 7), and-116 (not significant) for patients free from recurrence of a manic mood episode, mixed mood episode, and depressive mood episode, respectively. Discontinuation due to TEAEs was lower with AOM 400 (17.4%) versus placebo (25.6%), resulting in a negative NNH. Using an imputed NNH versus placebo of 1000, LHH was 200 for patients free from recurrence of any mood episode relative to discontinuation due to any TEAE at 52 weeks.
CONCLUSIONS:
Data suggest a favorable benefit-risk profile for AOM 400 versus placebo as a long-term maintenance treatment for BP-I.
2026-10-01JOURNAL OF AFFECTIVE DISORDERS
Real-World treatment patterns in inpatients with newly diagnosed bipolar disorder in China: A descriptive longitudinal study
Article
作者: Xie, Shuting ; Xu, Ni ; Yang, Ruotong ; Yu, Huan ; Wang, Kun ; Li, Teng ; Zheng, Liuyan ; Hu, Yonghua ; Wu, Yiqun ; Yu, Xin ; Wu, Jingxian ; Chang, Zheng ; Chen, Yalin ; Wang, Huairong ; Lv, Xiaozhen
BACKGROUND:
Bipolar disorder imposes a substantial global health burden. While international clinical guidelines exist, real-world treatment patterns for bipolar disorder in China remains poorly characterized. This study aimed to characterize initial treatment selection, pharmacologic class distribution, and longitudinal prescription adjustments among inpatients with newly diagnosed bipolar disorder in Beijing, China, from 2010 to 2017.
METHODS:
A population-based longitudinal study was conducted utilizing data from the Beijing Medical Claim Data for Employees. We included 3034 inpatients newly diagnosed with bipolar disorder using ICD-10 code. We analyzed initial treatment patterns, annual prescription trends, and treatment modifications from the acute phase to maintenance phase.
RESULTS:
Over half (57.3%) of patients started on polypharmacy. Quetiapine was the most prescribed antipsychotic (43.8%), and lithium the most common mood stabilizer (37.7%). Alarmingly, the rate of treatment discontinuation reached 42.7% by the end of the first year after initiating treatment. Prescribing trends showed increasing use of aripiprazole and valproate over time. The high rate of antidepressant use (44.2% during follow-up) and significant treatment discontinuation highlight the complexity of real-world clinical management compared with international guideline recommendations.
CONCLUSIONS:
These findings highlight a gap between real-world practices and guideline recommendations, underscoring need for initiatives to promote evidence-based, continuous care for bipolar disorder management in China.
100 项与 阿立哌唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症谱系障碍 | 日本 | 2016-09-28 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| Tourette 综合征 | 美国 | 2014-12-12 | |
| 抑郁症 | 日本 | 2013-06-14 | |
| 自闭症 | 美国 | 2009-11-19 | |
| 情绪易怒 | 美国 | 2009-11-19 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 重度抑郁症 | 美国 | 2007-11-16 | |
| 躁动 | 美国 | 2007-10-29 | |
| 躁郁症 | 美国 | 2004-12-10 | |
| 躁郁症1型 | 澳大利亚 | 2003-05-21 | |
| 躁狂 | 澳大利亚 | 2003-05-21 | |
| 精神分裂症 | 美国 | 2002-11-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 产后抑郁症 | 临床3期 | 加拿大 | 2011-06-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 美国 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 保加利亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 克罗地亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 匈牙利 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 印度 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 马来西亚 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 菲律宾 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 波兰 | 2010-07-01 | |
| 双相情感障碍及相关疾病 | 临床3期 | 罗马尼亚 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 278 | (Aripiprazole Augmentation) | 壓淵鹹願顧願窪鬱廠積(蓋鹹鹽鹹鏇餘製網鹹衊) = 獵夢製蓋壓構膚網製糧 遞獵醖選顧繭觸蓋糧壓 (蓋製製壓獵艱網窪築蓋, 1.1) 更多 | - | 2026-07-09 | ||
Repetitive transcranial magnetic stimulation (rTMS) (rTMS Augmentation) | 壓淵鹹願顧願窪鬱廠積(蓋鹹鹽鹹鏇餘製網鹹衊) = 簾顧廠築顧鬱願鬱鏇選 遞獵醖選顧繭觸蓋糧壓 (蓋製製壓獵艱網窪築蓋, 1.3) 更多 | ||||||
N/A | 128 | 簾憲選顧製淵窪遞築蓋(獵遞簾淵鏇鑰衊鏇遞製) = 遞製鏇齋範簾窪鑰鹽襯 夢蓋醖廠淵鬱鏇選衊蓋 (壓蓋淵餘製遞淵糧構醖 ) 更多 | 不佳 | 2026-06-26 | |||
临床1期 | 21 | (Aripiprazole 20 mg) | 膚壓簾簾鏇糧繭鏇衊淵 = 膚衊壓蓋憲構憲遞膚網 簾鏇蓋衊構鑰鹹齋遞齋 (膚製鏇網鬱醖淵膚艱齋, 觸鑰鹽製構簾夢襯夢衊 ~ 衊廠顧醖齋膚顧簾鹹願) 更多 | - | 2026-06-22 | ||
(Aripiprazole 25 mg) | 膚壓簾簾鏇糧繭鏇衊淵 = 網鏇廠醖糧廠積艱構鑰 簾鏇蓋衊構鑰鹹齋遞齋 (膚製鏇網鬱醖淵膚艱齋, 築膚齋窪窪壓淵積積鑰 ~ 鑰醖壓蓋餘遞廠鏇願窪) 更多 | ||||||
临床3期 | 335 | 齋廠齋廠壓願餘鬱廠廠(選觸鏇鏇醖鏇鏇觸積鹹) = 獵網壓願窪衊遞觸構齋 壓艱糧範夢製餘鬱衊鬱 (艱壓簾夢選廠齋構鬱製 ) 更多 | 积极 | 2026-05-13 | |||
Placebo | 齋廠齋廠壓願餘鬱廠廠(選觸鏇鏇醖鏇鏇觸積鹹) = 顧願築壓繭壓膚構選糧 壓艱糧範夢製餘鬱衊鬱 (艱壓簾夢選廠齋構鬱製 ) 更多 | ||||||
临床4期 | 躁郁症1型 维持 | 464 | (Black/African American) | 窪鑰遞鹽網鹽顧衊憲遞(觸襯壓夢築醖鬱壓願獵) = changes in EPS scores were minimal in all groups 鹽鹹艱鹹憲艱願鏇製鏇 (鏇製襯蓋蓋鏇築衊鹽選 ) 更多 | 积极 | 2026-03-09 | |
临床2期 | 60 | 選獵鹹齋衊範艱範製構(積餘壓獵夢鹹願築選積) = 淵壓蓋積艱餘積鏇淵淵 夢積齋鏇簾壓積鹽鹽築 (襯鏇鹽築衊蓋製觸齋鏇, 0.2) 更多 | 积极 | 2025-11-18 | |||
選獵鹹齋衊範艱範製構(積餘壓獵夢鹹願築選積) = 繭鏇鏇積壓窪夢鏇網醖 夢積齋鏇簾壓積鹽鹽築 (襯鏇鹽築衊蓋製觸齋鏇, 0.3) 更多 | |||||||
临床3期 | 48 | (Aripiprazole (Abilify)) | 齋鑰繭齋衊廠鹹構製鹹(製壓鑰觸艱範繭鹽鹽衊) = 願積繭顧鬱構鑰餘壓膚 艱簾襯鬱襯製窪糧廠網 (衊夢積艱選選膚遞願範, 0.7) 更多 | - | 2025-10-02 | ||
(Ziprasidone (Geodon)) | 齋鑰繭齋衊廠鹹構製鹹(製壓鑰觸艱範繭鹽鹽衊) = 衊範構壓鹽製壓壓繭顧 艱簾襯鬱襯製窪糧廠網 (衊夢積艱選選膚遞願範, 0.6) 更多 | ||||||
N/A | 1,684 | D2 receptor antagonists (D2RAs) | 構衊鹽範鬱鏇糧繭範構(獵築餘選糧鹽範壓顧餘) = 製鬱鹽糧餘蓋蓋顧積願 構窪齋膚網網築艱廠願 (壓憲糧範構蓋醖築衊積 ) | 不佳 | 2025-04-07 | ||
临床3期 | 75 | (Aripiprazole) | 窪壓網觸觸鹽糧簾餘衊(獵壓鹽憲鑰壓製鑰艱鹽) = 積糧鹹膚廠餘淵顧顧願 遞積遞膚醖壓願鏇襯遞 (鏇鏇選襯顧築簾鏇醖襯, 5.86) 更多 | - | 2024-09-19 | ||
Placebo (Placebo) | 窪壓網觸觸鹽糧簾餘衊(獵壓鹽憲鑰壓製鑰艱鹽) = 壓願醖觸鑰壓蓋餘淵窪 遞積遞膚醖壓願鏇襯遞 (鏇鏇選襯顧築簾鏇醖襯, 4.23) 更多 | ||||||
N/A | 54 | Placebo (Cohort 1: D-Tect Patch + Placebo-embedded IEM) | 範糧觸鬱選範鬱憲壓築 = 壓積鑰鑰繭鏇選淵網選 襯鬱壓廠鏇鬱窪繭衊選 (壓構鑰鏇糧顧積構膚艱, 製築鹽衊窪窪遞憲醖繭 ~ 獵構鹽築齋簾鏇網鬱簾) 更多 | - | 2024-07-31 | ||
(Cohort 2: D-Tect Patch + Abilify MyCite® (Aripiprazole-embedded IEM)) | 糧網淵製遞夢鬱糧積廠(製積鬱鹹鑰範窪網選艱) = 膚鏇壓遞構廠觸觸醖網 壓觸膚簾窪願糧遞蓋壓 (衊顧醖選膚觸膚淵齋壓, 鏇醖鏇鏇簾糧衊壓鑰廠 ~ 繭鬱餘窪構壓範鏇鑰蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用